Wegovy vs Ozempic, Zepbound vs Mounjaro

Is Wegovy the same as Ozempic?

Yes, the active ingredient is the same. Both are semaglutide, a GLP-1 receptor agonist made by Novo Nordisk, injected under the skin once a week. What differs is the approval behind each brand, the doses each label goes up to, and the pens they come in.

Think of the brand as the label that comes with the molecule. The label sets who it is approved for, the dose steps, and the highest dose. That is why a pharmacist cannot hand you Ozempic for a Wegovy prescription, or the other way round.

Is Zepbound the same as Mounjaro?

Yes. Both are tirzepatide, made by Eli Lilly, a single molecule that acts on both the GIP and GLP-1 receptors. Unlike the semaglutide pair, Zepbound and Mounjaro share the same dose strengths and the same top dose in adults. The difference is the approved use: weight management and sleep apnea for Zepbound, type 2 diabetes for Mounjaro.

Outside the US, the names can work differently. In Mexico and much of Latin America, tirzepatide is sold as Mounjaro, and what it is approved for locally can differ from the US label.

How do the four brands compare?

This table summarizes the current US prescribing information for each brand.

There are tablets in both semaglutide families too. Wegovy tablets are a daily pill for weight management, covered in our Wegovy pill guide. For type 2 diabetes, oral semaglutide is sold as Rybelsus and, more recently in the US, as Ozempic tablets.

How do the dose ladders differ?

The ladders differ most between Wegovy and Ozempic. Both start at 0.25 mg once a week for 4 weeks, then go to 0.5 mg. After that they split.

The Wegovy ladder is a fixed climb toward 2.4 mg. The Ozempic ladder only climbs if blood sugar needs more control. The 0.25 mg step on both labels is a starting dose to help the gut adjust.

Zepbound and Mounjaro follow the same ladder: 2.5 mg weekly for 4 weeks, then up in 2.5 mg steps after at least 4 weeks on the current dose. The 2.5 mg dose is for getting started. The Zepbound label lists 5, 10 or 15 mg as maintenance doses for weight, and 10 or 15 mg for sleep apnea. The Mounjaro label raises the dose only if more blood sugar control is needed.

These are descriptions of the labels, not a plan for you. Your prescriber sets your dose and decides if and when it changes. Our titration schedules tool lays out each label's steps side by side.

What is Wegovy HD, the 7.2 mg dose?

Wegovy HD is a 7.2 mg once-weekly Wegovy injection, the highest weekly semaglutide injection on any US label. The label allows it for adults using Wegovy for weight reduction who have tolerated 2.4 mg for at least 4 weeks, when more weight reduction is clinically indicated. It comes as its own single-dose pen.

In the label's 72-week trial in adults with obesity and without diabetes, average weight change was:

In a second trial in adults with type 2 diabetes and obesity, average change was -13.2% on 7.2 mg, -10.4% on 2.4 mg and -3.8% on placebo.

The higher dose came with more side effects. Nausea was reported by 39% on 7.2 mg vs 35% on 2.4 mg and 13% on placebo, and vomiting by 22% vs 16% and 6%. Altered skin sensations, such as tingling, burning or sensitive skin (the label calls this dysesthesia), were reported by 22% on 7.2 mg vs 6% on 2.4 mg. The label's 7.2 mg approval is only for weight reduction in adults, not for teens or MASH. Ozempic has no 7.2 mg dose.

How are the pens different?

The pens are not interchangeable, even within a molecule. Each brand has its own devices, and the label asks your care team to train you on the specific one you receive.

• Wegovy mostly comes in single-dose pens, one per week, with one pen strength for each step (0.25, 0.5, 1, 1.7, 2.4 and 7.2 mg). There are also single-dose syringes and a FlexTouch pen that delivers four 2.4 mg doses.
• Ozempic comes in multi-dose pens that hold several weekly doses, with a separate pen for each dose level, plus single-dose prefilled syringes for some doses.
• Zepbound and Mounjaro come in single-dose pens, single-dose vials, multi-dose vials and a KwikPen that holds four doses, in strengths from 2.5 to 15 mg.

Multi-dose and multi-use pens are for one person only and must never be shared, even with a new needle. If your prescription changes from one device to another, ask for a new walkthrough.

Why do insurers treat them differently?

Insurance plans usually cover a medicine for a specific use, and the use comes from the FDA approval and your diagnosis. So a plan can cover Ozempic or Mounjaro for type 2 diabetes and still exclude Wegovy or Zepbound for weight management, even though the molecule is the same. Plans often ask your prescriber for prior authorization showing the diagnosis that matches the brand's approved use.

Newer approvals can change the picture. Wegovy's heart risk approval and Zepbound's sleep apnea approval give some plans a covered reason that weight management alone did not. Coverage rules vary by plan, employer and year, so the best source is your plan's drug list and your prescriber's office.

What this does not mean is that a diabetes brand can be prescribed for weight loss to get coverage. A plan that covers Ozempic for type 2 diabetes is covering that approved use.

Why is switching between them a prescriber decision?

Switching brands is a prescriber decision because the brands differ in dose steps, strengths and devices, and the labels have their own rules for starting, missed doses and changes. A 1 mg Ozempic dose and a 1 mg Wegovy dose contain the same molecule, but the devices, the dose ladders and the treatment plan around them are different.

There is also a safety reason. The labels say not to combine a semaglutide or tirzepatide product with another GLP-1 medicine, so there should never be overlap between two brands. Your prescriber decides the new brand, the starting dose and the timing. For anything about switching, missed doses or stopping, follow your prescriber and the label.

The side effects are the same kind across each pair: mostly nausea, diarrhea, vomiting and constipation, most common during step-ups. See Wegovy and Ozempic side effects and Zepbound and Mounjaro side effects.

Whichever brand you use, contact your clinician or seek care for severe stomach pain that will not go away (sometimes spreading to your back), vomiting that stops you keeping fluids down, signs of an allergic reaction, or a lump or swelling in your neck.

If you are comparing semaglutide with tirzepatide rather than two brands of the same one, see semaglutide vs tirzepatide.

Questions

Keep reading

Educational information, not medical advice. Talk to your clinician about your treatment.